drugset / Trial / NCT00418821

A Study of the Effect of Aldurazyme® (Laronidase) Treatment on Lactation in Female Patients With Mucopolysaccharidosis I (MPS I) and Their Breastfed Infants

NCT00418821

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to determine if laronidase is present in the breast milk of post-partum women receiving Aldurazyme® (laronidase) and the effects of Aldurazyme (laronidase) on the growth, development, and immunologic response of their breastfed infants.

Timeline

Start
2010-10-22
Primary completion
2022-12-21
Completion
2022-12-21

Drugs

EvaluationDrugModalityDoseRoute
Subject laronidase Protein / enzyme biologic 0.58 mg/kg Intravenous